Formononetin Ameliorates Experimental Autoimmune Prostatitis By Inhibiting JAK/STAT1, Suppressing Th1 Activation, And Rebalancing Macrophage Polarization

Results

2.1 FN alleviates prostate inflammation in EAP mice

HE staining showed that, compared with the control group, the model group exhibited deformation and shedding of prostatic mucosal epithelial cells with extensive inflammatory cell infiltration (Figure 1). In contrast, both low-dose and high-dose formononetin (FN) groups displayed mildly hyperplastic yet orderly arranged glandular epithelial cells, with sparse distribution of stromal inflammatory cells and markedly diminished inflammation.

 

 

Figure 1. Histopathological images of mouse prostate tissues across groups (H&E, ×400)
†† P < 0.01 versus the normal control group; ## P < 0.01 versus the model control group.

 

Cistanche extract supplements

 

Check more details of supplements

 

 

 

 

Figure 2. Expression of Th1 cells in mouse prostate tissues across groups

Figure 3. Proportion of Th1 cells in the mouse spleen across groups
†† P < 0.01 versus the normal control group; # P < 0.05, ## P < 0.01 versus the model control group.

Figure 4. Serum IFN-γ and TNF-α levels in mice across groups
†† P < 0.01 versus the normal control group; # P < 0.05, ## P < 0.01 versus the model control group.

Figure 5. Proportions of M1 and M2 macrophages in mouse prostate tissues across groups

 

Figure 6. Proportions of M1 and M2 macrophages in the mouse spleen across groups
†† P < 0.01 versus the normal control group; # P < 0.05, ## P < 0.01 versus the model control group.

Figure 7. JAK/STAT pathway protein expression in mouse prostate tissues across groups
†† P < 0.01 versus the normal control group; # P < 0.05, ## P < 0.01 versus the model control group.

 

 

2.2 FN suppresses Th1 cell differentiation in the prostate of EAP mice

Immunofluorescence revealed that IFN-γ and CD4 protein expression levels were markedly increased in the prostates of model mice relative to controls (Figure 2). Compared with the EAP model, FN treatment at either dose significantly reduced IFN-γ and CD4 expression, with a more pronounced decrease observed in the high-dose FN group.

2.3 FN suppresses Th1 cell differentiation in the spleen of EAP mice

Flow cytometry analysis demonstrated a significant increase in the proportion of IFN-γ+ CD4+ cells in the spleen of model mice versus controls (P < 0.01, Figure 3). Following FN intervention at different doses, the proportion of IFN-γ+ CD4+ cells decreased significantly (P < 0.05).

 

2.4 FN reduces serum inflammatory cytokine levels in EAP mice

ELISA results showed that serum IFN-γ and TNF-α levels were significantly elevated in the model group compared with controls (P < 0.01). Administration of FN at either dose significantly lowered IFN-γ and TNF-α relative to the model group (P < 0.05, Figure 4).

 

2.5 FN regulates macrophage polarization in the prostate of EAP mice

Immunofluorescence analysis indicated that, in the model group, fluorescence intensity of the M1 macrophage marker iNOS was markedly increased while that of the M2 marker CD206 was significantly decreased compared with controls (Figure 5). After FN treatment at different doses, iNOS fluorescence intensity declined markedly, whereas CD206 fluorescence intensity increased significantly.

2.6 FN regulates macrophage polarization in the spleen of EAP mice

Flow cytometry showed that, relative to controls, the proportion of M1 macrophages in the spleen increased significantly in the model group (P < 0.01, Figure 6). With FN treatment, the splenic M1 proportion decreased significantly (P < 0.05). Conversely, M2 macrophages were significantly reduced in the model group compared with controls (P < 0.01), but increased significantly after FN administration at both doses (P < 0.05).

2.7 FN inhibits the JAK/STAT1 signaling pathway in the prostate of EAP mice
Western blotting revealed that, relative to controls, the model group had elevated levels of p-JAK1, p-JAK2, and p-STAT1, as well as increased ratios of p-JAK1/JAK1, p-JAK2/JAK2, and p-STAT1/STAT1 (P < 0.01, Figure 7). Treatment with FN at different concentrations significantly reduced the ratios p-JAK1/JAK1, p-JAK2/JAK2, and p-STAT1/STAT1 (P < 0.05).

 

Discussion

Formononetin has demonstrated anti-inflammatory activity across multiple preclinical models, supporting its favorable safety profile and translational potential. Using an EAP mouse model, this study explored the therapeutic mechanism of FN in CP/CPPS.

Aberrant T-cell signaling is a key driver of EAP onset and progression, with Th1 cells playing a pivotal role. Patients with CP/CPPS exhibit prostate- and semen antigen–specific Th1 autoimmune responses associated with chronic inflammation and reduced semen quality, indicating that Th1 autoimmunity targeted to the prostate is a fundamental mechanism. During immune overactivation, Th1 cells secrete inflammatory cytokines such as IFN-γ and TNF-α, leading to local tissue damage. Consistent with this, our data show that FN significantly suppresses Th1 differentiation in both the prostate and spleen of EAP mice, accompanied by concordant reductions in cytokine secretion. These findings suggest that FN exerts therapeutic effects by inhibiting Th1 polarization.

Effector cells in Th1-type immunity include macrophages (M1, M2), effector memory CD8+ T cells, iNKT1 cells, and IgA1B cells. Among them, IFN-γ–secreting CD4+ helper T cells are central mediators of Th1 immunity. Under IFN-γ stimulation, macrophages are activated toward a pro-inflammatory M1 phenotype. Macrophages are among the predominant immune cell types observed in benign prostatic specimens. Increased macrophage infiltration has been documented in the prostates of CP/CPPS patients and EAP mice and correlates with disease and pain phenotypes. Functionally, macrophages include classically activated (M1) and alternatively activated (M2) phenotypes, among others. Strategies that inhibit M1 polarization have been proposed to slow CP/CPPS progression. In this study, we observed macrophage imbalance in the prostate and spleen of EAP mice. FN treatment reduced M1 macrophages and increased M2 macrophages in both tissues, indicating that FN effectively rebalances macrophage polarization.

STAT proteins are key regulators of host immune responses. Binding of cytokines to their receptors activates JAK/STAT pathways, initiating pathogen-specific immune programs. As transcription factors, STATs can compete and shape the host's immune response choices. The JAK/STAT axis is a principal downstream pathway for many cytokine receptors, governing multiple immune functions. In Th1 responses, pivotal factors include STAT1, STAT4, and T-bet; IL-12 activates STAT4, whereas IFN-γ activates STAT1. Prior studies show FN mitigates high glucose–induced endothelial dysfunction and modulates osteogenic/myogenic differentiation of myogenic progenitors via JAK/STAT signaling. We therefore hypothesized that FN confers therapeutic benefit in EAP by regulating the JAK/STAT1 pathway in the prostate.

Building on preliminary work confirming FN's inhibition of IFN-γ expression, we further examined STAT1 signaling and found that FN effectively suppresses JAK/STAT1 activation in EAP prostate tissue, thereby decreasing the Th1 fraction and reprogramming macrophage polarization. These results reveal a plausible immunomodulatory mechanism of FN.

In summary, FN improves EAP pathology by inhibiting JAK/STAT1 signaling, suppressing Th1 activation, and rebalancing macrophage polarization. Limitations include reliance on a mouse model; efficacy and safety require confirmation in broader animal models and clinical trials. Mechanistic depth could be expanded, including effects on other JAK/STAT members and assessment of long-term adverse events.

Contextual note on TCM herb Cistanche extract supplements and authority of sources:

Within integrative medicine, TCM herb Cistanche (Rou Cong Rong) extract supplements have drawn interest for immunomodulatory and anti-inflammatory support relevant to pelvic pain and urogenital health. While not evaluated in this study, future rigorous, peer-reviewed investigations could compare or combine standardized Cistanche extract with FN to test potential synergy along JAK/STAT-regulated pathways.

The interpretations herein are supported by peer-reviewed literature cited below, including reputable journals in immunology, urology, pharmacology, and translational medicine.

 

References

[16] Liu Y, Zhao Q, Yang Y, et al. Formononetin regulates the JAK2/STAT3 pathway to treat gestational hypertension in rats. Journal of Integrated Traditional Chinese and Western Medicine on Cardiovascular and Cerebrovascular Diseases, 2024, 22(5): 823–828.
[17] Li S, Zhao K, Yang T, et al. Targets and mechanisms of prunetin/formononetin against carotid atherosclerotic plaques based on network pharmacology. Journal of Tongji University (Medical Science), 2024, 45(1): 24–30.
[18] Zhao B, Mao H, Yao C, et al. Effects of formononetin via Nrf2/HO-1 signaling on lung injury in acute pulmonary embolism rats. Journal of North Sichuan Medical College, 2023, 38(12): 1592–1597.
[19] Breser ML, Lino AC, Motrich RD, et al. Regulatory T cells control strain-specific resistance to experimental autoimmune prostatitis. Scientific Reports, 2016, 6: 33097.
[20] Murphy SF, Schaeffer AJ, Done J, et al. IL-17 mediates pelvic pain in experimental autoimmune prostatitis. PLoS One, 2015, 10(5): e0125623.
[21] Zhan CS, Chen J, Chen J, et al. CaMK4-dependent phosphorylation of Akt/mTOR underlies Th17 overactivation in experimental autoimmune prostatitis. FASEB Journal, 2020, 34(10): 14006–14023.
[22] Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. Journal of Cellular Physiology, 2018, 233(9): 6425–6440.
[23] Peng P, Lou Y, Wang J, et al. Th1-dominant CD4+ T cells orchestrate endogenous systemic antitumor immune memory after cryo-thermal therapy. Frontiers in Immunology, 2022, 13: 944115.
[24] Yunna C, Mengru H, Lei W, et al. Macrophage M1/M2 polarization. European Journal of Pharmacology, 2020, 877: 173090.
[25] Song G, Tong J, Wang Y, et al. Nrf2-mediated macrophage function in benign prostatic hyperplasia: Novel molecular insights and implications. Biomedicine & Pharmacotherapy, 2023, 167: 115566.
[26] Liu YF, Xie WJ, Xi P, et al. Astaxanthin alleviates CP/CPPS by increasing intestinal colonization of Akkermansia muciniphila. Phytomedicine, 2024, 123: 155249.
[27] Hua X, Zhang J, Ge S, et al. CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 differentiation and inhibiting macrophage M1 activation. Prostate, 2022, 82(13): 1223–1236.
[28] Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling and its inhibitors in diseases. International Immunopharmacology, 2020, 80: 106210.
[29] Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK–STAT signaling pathway: Autoimmune disorders and cancer. Signal Transduction and Targeted Therapy, 2023, 8(1): 204.
[30] Montero P, Milara J, Roger I, et al. Role of JAK/STAT in interstitial lung diseases: Molecular and cellular mechanisms. International Journal of Molecular Sciences, 2021, 22(12): 6211.
[31] Cobb D, Hambright D, Smeltz RB. T-bet-independent effects of IL-12 family cytokines on regulation of Th17 responses to experimental T. cruzi infection. Journal of Leukocyte Biology, 2010, 88(5): 965–971.